Similar articles

• [Better prognosis in hypertension and left ventricular hypertrophy. LIFE Study sets new standard].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2002 May 16;144(20):60-1. MMW Fortschr Med. 2002. PMID: 12119887 German. No abstract available.
• [Isolated systolic hypertension. "AT1 blocker preferred over beta-blocker"].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2002 Sep 19;144(38):14. MMW Fortschr Med. 2002. PMID: 12395694 German. No abstract available.
• [What are the consequences of the LIFE Study for general practice].

  Zidek W. Zidek W. MMW Fortschr Med. 2002 Sep 19;144(38):48. MMW Fortschr Med. 2002. PMID: 12395704 German. No abstract available.
• Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.

  Devereux RB, Dahlöf B. Devereux RB, et al. Curr Med Res Opin. 2007 Feb;23(2):443-57. doi: 10.1185/030079906X167435. Curr Med Res Opin. 2007. PMID: 17288698 Review.
• [Results from the LIFE study: promising effects of new hypertensive agents].

  Nilsson P, Kahan T. Nilsson P, et al. Lakartidningen. 2002 Apr 18;99(16):1792-4. Lakartidningen. 2002. PMID: 12043477 Review. Swedish. No abstract available.